Evidence map›Paper›PMID 30467203›Full record

Trial reportHaematologica2019

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Hugo F Fernandez, Zhuoxin Sun, Mark R Litzow, Selina M Luger, Elisabeth Paietta, Janis Racevskis, Ross L Levine, Jay P Patel, Omar Abdel-Wahab, Rhett P Ketterling and 5 more

Abstract readLetterMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Zebrafish models of acute leukemias: Current models and future directions.Wiley interdisciplinary reviews. Developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hugo F FernandezDepartment of Malignant Hematology & Cellular Therapy, Moffitt Cancer Center, Tampa, FL, USA hufernandez@mhs.net.
Zhuoxin SunDepartment of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA, USA.
Mark R LitzowDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Selina M LugerAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Elisabeth PaiettaMontefiore Medical Center, Bronx, NY, USA.
Janis RacevskisNorth Division, Montefiore Medical Center, Bronx, NY, USA.
Ross L LevineHuman Oncology and Pathogenesis Program, Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Jay P PatelHuman Oncology and Pathogenesis Program, Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Omar Abdel-WahabHuman Oncology and Pathogenesis Program, Department of Medicine Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Rhett P KetterlingDivision of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Gordon W DewaldDivision of Cytogenetics, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
John M BennettHematology/Oncology/Pathology, University of Rochester, Rochester, NY, USA.
Jacob M RoweHematology and Bone Marrow Transplantation, Rambam Medical Center, Technion, Haifa, Israel.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Martin S TallmanLeukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCI NIH HHS P30 CA008748NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA233290
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAntibiotics, AntineoplasticDaunorubicinDisease-Free SurvivalFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedSurvival RateAntibiotics, AntineoplasticDaunorubicin

Identifiers

PMID30467203
PMCPMC6442974

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.